tazobactam has been researched along with ljc 10627 in 4 studies
Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (ljc 10627) | Trials (ljc 10627) | Recent Studies (post-2010) (ljc 10627) |
---|---|---|---|---|---|
1,327 | 153 | 694 | 176 | 31 | 52 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abendroth, J; Atkins, K; Boyer, SH; Clifton, MC; Dudley, MN; Durso, S; Griffith, DC; Hecker, SJ; Hirst, GC; King, P; Lomovskaya, O; Loutit, JS; Morgan, EE; Potts, KT; Raymond, A; Reddy, KR; Sabet, M; Sun, D; Tarazi, Z; Totrov, M; Tsivkovski, R | 1 |
Appelbaum, PC; Jacobs, MR; Spangler, SK | 1 |
Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
Barnes, SW; Dean, CR; Iartchouk, O; Jones, AK; Lee, PS; Mostafavi, M; Ranjitkar, S; Walker, JR; Willis, TW; Zwirko, Z | 1 |
4 other study(ies) available for tazobactam and ljc 10627
Article | Year |
---|---|
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Heterocyclic Compounds, 1-Ring; Mice; Microbial Sensitivity Tests; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship | 2015 |
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Drug Combinations; Drug Therapy, Combination; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Spectinomycin; Tazobactam; Thienamycins; Virginiamycin | 1993 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Target (MexB)- and Efflux-Based Mechanisms Decreasing the Effectiveness of the Efflux Pump Inhibitor D13-9001 in
Topics: beta-Lactams; Imipenem; Microbial Sensitivity Tests; Monobactams; Piperidines; Pseudomonas aeruginosa; Quaternary Ammonium Compounds; Tazobactam; Thienamycins; Transcriptome | 2019 |